Savara Inc
NASDAQ: SVRA · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-06-05
Savara Inc (SVRA) Financial statements
SEC filings — annual and quarterly data.
Margin trends — annual
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | — | $-29.33M | — | — | — |
| 2007 | $500000.00 | $-22.14M | 100.00% | -4,862.21% | -4,428.41% |
| 2008 | $500000.00 | $-26.65M | 100.00% | -5,461.97% | -5,329.50% |
| 2009 | $300000.00 | $-11.33M | 100.00% | -3,761.90% | -3,775.02% |
| 2010 | $488959.00 | $-8.45M | 100.00% | -1,746.51% | -1,728.35% |
| 2011 | $0.00 | $-13.26M | — | — | — |
| 2012 | $0.00 | $-15.56M | — | — | — |
| 2013 | $0.00 | $-21.48M | — | — | — |
| 2014 | $1548.00 | $-28.70M | 100.00% | -1,891,408.27% | -1,854,134.37% |
| 2015 | $54.00 | $-39.84M | -270,270.37% | -72,912,962.96% | -73,781,481.48% |
| 2016 | $400000.00 | $-10.92M | 100.00% | -2,737.00% | -2,730.75% |
| 2017 | $0.00 | $-29.80M | — | — | — |
| 2018 | $0.00 | $-61.52M | — | — | — |
| 2019 | $0.00 | $-78.17M | — | — | — |
| 2020 | $257000.00 | $-49.62M | -13,533.46% | -19,182.88% | -19,305.45% |
| 2021 | $1000.00 | $-43.01M | -2,899,100.00% | -4,147,700.00% | -4,301,400.00% |
| 2022 | $0.00 | $-38.15M | — | — | — |
| 2023 | $0.00 | $-54.70M | — | — | — |
| 2024 | $0.00 | $-95.88M | — | — | — |
| 2025 | $0.00 | $-118.84M | — | — | — |
Frequently asked questions
What is Savara Inc's revenue?
Savara Inc's trailing twelve-month revenue is $1000.00. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How much free cash flow does SVRA generate?
SVRA produced $-101.06M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is SVRA's balance sheet healthy?
SVRA holds $33.18M in cash and equivalents against $29.91M in long-term debt, on $203.13M of shareholder equity. Cash on hand exceeds long-term debt, so the balance sheet adds little financial risk to the thesis.